The Zacks Analyst Blog Highlights Novo Nordisk, Advanced Micro Devices, Netflix, Merck, and Marsh & McLennan

In this article:

For Immediate Release

Chicago, IL – April 27, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S NVO, Advanced Micro Devices, Inc. AMD, Netflix, Inc. NFLX, Merck & Co., Inc. MRK, and Marsh & McLennan Companies, Inc. MMC.

Here are highlights from Tuesday’s Analyst Blog:

Top Research Reports for Novo Nordisk, AMD and Netflix

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, Advanced Micro Devices, Inc., and Netflix, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
 
You can see all of today's research reports here >>>

Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+53% vs. +28.4%). Novo Nordisk's marketed diabetes drug, Ozempic, is off to a solid start. The launch of Rybelsus also looks impressive. Yearly growth is driven by all geographical areas. Novo Nordisk has one of the broadest diabetes portfolios in the industry. Ozempic, Rybelsus, Xultophy and Saxenda have been helping the company maintain momentum.

The Zacks analyst believes that Label expansion of these existing drugs is expected to further boost sales. However, lower realized prices in the Unites States, loss of exclusivity for products and stiff competition are affecting sales. Sales are also being negatively impacted by the COVID-19 pandemic. Also, the supply challenges for Wegovy has hurt the stock. The patent expiry on some of the products in Novo Nordisk's portfolio is concerning too.

(You can read the full research report on Novo Nordisk here >>>)

Advanced Micro Devices shares have gained +2.2% over the past year against the Zacks Electronics - Semiconductors industry's gain of +4.4%. The company is benefiting from strong demand of its Ryzen and EPYC server processors, courtesy of the increasing proliferation of Artificial Intelligence (AI) and Machine Learning (ML) in industries like cloud, gaming and data center. The growing clout of 7 nanometer (nm) products in the data center vertical, driven by work-from-home and online learning trends, is a key catalyst. AMD provided strong 2022 guidance for revenues backed by robust growth across all businesses.

Higher server and client processor revenues are likely to lead to a sequential increase. The Xilinx and Pensando acquisitions will bolster AMD's data center business. Alliances with Amazon, Microsoft, Baidu and JD.com are likely to augment business prospects. However, stiff competition from NVIDIA and Intel remains a concern.

(You can read the full research report on Advanced Micro Devices here >>>)

Netflix shares have declined -60.0% over the past year against the Zacks Broadcast Radio and Television industry's decline of -43.0%. The company is suffering from stiff competition in the streaming space like Apple, Amazon prime video, HBO Max, Disney+, Peacock, Paramount+ and TikTok. The company's leveraged balance sheet and higher streaming obligation are major concerns. Stiff competition, the unfavorable impact of account sharing, sluggish economic growth, increasing inflation, the Russia-Ukraine conflict and some continued disruptions from COVID-19.

However, Netflix is expected to continue to dominate the streaming space, courtesy of its diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content.

(You can read the full research report on Netflix here >>>)

Other noteworthy reports we are featuring today include Merck & Co., Inc., and Marsh & McLennan Companies, Inc.

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
 
Novo Nordisk AS (NVO) : Free Stock Analysis Report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Netflix, Inc. (NFLX) : Free Stock Analysis Report
 
Marsh & McLennan Companies, Inc. (MMC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement